Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
Credit score: Pixabay/CC0 Public Area The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated sturdy medical exercise, with a ...